Important safety information for SLUMBARA.
Review contraindications, precautions, adverse reactions, and clinical-trial findings for SLUMBARA.
Who should not take SLUMBARA
- Patients taking dual orexin receptor antagonists, chronoactive benzodiazepine analogs, or phospholattice sedatives
- Patients with a history of paradoxical nocturnal orientation episodes
- Patients with severe hepatic mesh impairment or untreated circadian dissociation disorder
- Patients who must be fully alert within 6 hours of dosing
Most common adverse reactions
Metallic mouth feel, delayed orientation upon waking, dry mouth, ambient softness perception, next-morning coordination changes, unusually vivid recollection of unfinished tasks, and transient emotional flattening during the first week of therapy.
Rare but serious events included sleep-transition confusion, reversible dawn dysphoria, and involuntary task-list generation between 3:00 and 4:00 a.m.
Potential interactions and precautions
CNS-active medicines
Co-administration with hypnotics, orexin antagonists, barbiturate analogs, or sedative antihistamines may increase the risk of excessive continuity suppression and delayed morning release.
CYP pathways
Arvethadone mesylate is primarily metabolized through CYP3A9-N and CYP2B17. Strong inhibitors may raise overnight exposure; inducers may shorten continuity coverage.
Alcohol
Alcohol may intensify sleep-transition confusion and increase reports of perceived environmental softness or altered hallway depth.
Summary of clinical findings
| Study | Population | Design | Key result |
|---|---|---|---|
| LANTERN-1 | n=612 adults with moderate to severe NCD | 12-week randomized, double-blind, placebo-controlled | -54 min mean nocturnal wake time vs baseline; placebo -18 min |
| LANTERN-2 | n=488 adults with recurrent continuity collapse | 12-week randomized active-comparator study | 34% greater improvement in return-to-sleep latency vs comparator |
| LANTERN-LT | n=703 continuing participants | 52-week extension | Continuity benefits maintained through 1 year with stable adverse-event profile |
What patients should know before taking SLUMBARA
- Take once nightly only when able to remain in bed for a full night
- Do not redose after an overnight awakening
- Avoid complex tasks until you know how SLUMBARA affects you the next morning
- Contact your healthcare provider if you experience persistent memory seams, sleep-transition confusion, or mood changes
Special populations
Older adults: Consider starting at 12 mg.
Hepatic impairment: Reduced exposure clearance may prolong release.
Pregnancy/lactation: No adequate data are available; evaluate risk-benefit.
About this experience
This website is a satirical brand experience created for entertainment and storytelling purposes. SLUMBARA, Elara Therapeutics, and all related conditions, trial programs, claims, and product information presented here are fictional.